FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993964230> ?p ?o ?g. }

• W2993964230 endingPage "181" @default.
• W2993964230 startingPage "171" @default.
• W2993964230 abstract "Biosimilars are highly similar to the licensed biologic (“reference product”), with no clinically meaningful differences in safety, purity, or potency between the two products. This comparative 52-week clinical study evaluated the efficacy, safety, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-05280586 (Ruxience™ [a rituximab biosimilar]) versus rituximab reference product sourced from the EU (MabThera®; rituximab-EU). Subjects with CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL) and an Eastern Cooperative Oncology Group performance status 0–1 were randomized (1:1) to PF-05280586 or rituximab-EU (375 mg/m2 intravenously [once weekly for 4 weeks at days 1, 8, 15, and 22]), stratified using the Follicular Lymphoma International Prognostic Index 2 classification. The primary endpoint was overall response rate (ORR) at week 26 (percentage of subjects achieving complete response [CR] or partial response [PR]). Therapeutic equivalence was concluded if the two-sided 95% confidence interval (CI) for the difference in ORR between groups was within the prespecified margin (± 16%). Secondary endpoints included progression-free survival (PFS), CR rate, safety, immunogenicity, PK, and PD. A total of 394 subjects were randomized: PF-05280586 (n = 196) or rituximab-EU (n = 198). ORR at week 26 was 75.5% (PF-05280586) versus 70.7% (rituximab-EU), for a difference of 4.66%; 95% CI (− 4.16 to 13.47), which was entirely within the prespecified equivalence margin. Rates of CR were 29.3% (PF-05280586) versus 31.0% (rituximab-EU). Estimated 1-year PFS rates were 78.2% (95% CI 70.2–84.2) and 83.0% (95% CI 75.0–88.6) for PF-05280586 and rituximab-EU, respectively. Safety, immunogenicity, and mean serum concentrations were similar between groups. The efficacy, safety, immunogenicity, PK, and PD of PF-05280586 and rituximab-EU were similar up to week 52 in subjects with previously untreated CD20-positive LTB-FL. ClinicalTrials.gov, NCT02213263 and EudraCT (2014-000132-41)." @default.
• W2993964230 created "2019-12-13" @default.
• W2993964230 creator A5013007045 @default.
• W2993964230 creator A5035120955 @default.
• W2993964230 creator A5056287200 @default.
• W2993964230 creator A5069923067 @default.
• W2993964230 creator A5071466957 @default.
• W2993964230 creator A5071760835 @default.
• W2993964230 creator A5083528186 @default.
• W2993964230 creator A5085810268 @default.
• W2993964230 date "2019-12-09" @default.
• W2993964230 modified "2023-10-06" @default.
• W2993964230 title "A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)" @default.
• W2993964230 cites W1970648523 @default.
• W2993964230 cites W2036721571 @default.
• W2993964230 cites W2049274660 @default.
• W2993964230 cites W2116895103 @default.
• W2993964230 cites W2122633654 @default.
• W2993964230 cites W2133201432 @default.
• W2993964230 cites W2136326451 @default.
• W2993964230 cites W2140341488 @default.
• W2993964230 cites W2275194275 @default.
• W2993964230 cites W2514392074 @default.
• W2993964230 cites W2553233139 @default.
• W2993964230 cites W2734929604 @default.
• W2993964230 cites W2736281699 @default.
• W2993964230 cites W2802364203 @default.
• W2993964230 cites W2898856153 @default.
• W2993964230 doi "https://doi.org/10.1007/s40259-019-00398-7" @default.
• W2993964230 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7113218" @default.
• W2993964230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31820339" @default.
• W2993964230 hasPublicationYear "2019" @default.
• W2993964230 type Work @default.
• W2993964230 sameAs 2993964230 @default.
• W2993964230 citedByCount "27" @default.
• W2993964230 countsByYear W29939642302019 @default.
• W2993964230 countsByYear W29939642302020 @default.
• W2993964230 countsByYear W29939642302021 @default.
• W2993964230 countsByYear W29939642302022 @default.
• W2993964230 countsByYear W29939642302023 @default.
• W2993964230 crossrefType "journal-article" @default.
• W2993964230 hasAuthorship W2993964230A5013007045 @default.
• W2993964230 hasAuthorship W2993964230A5035120955 @default.
• W2993964230 hasAuthorship W2993964230A5056287200 @default.
• W2993964230 hasAuthorship W2993964230A5069923067 @default.
• W2993964230 hasAuthorship W2993964230A5071466957 @default.
• W2993964230 hasAuthorship W2993964230A5071760835 @default.
• W2993964230 hasAuthorship W2993964230A5083528186 @default.
• W2993964230 hasAuthorship W2993964230A5085810268 @default.
• W2993964230 hasBestOaLocation W29939642301 @default.
• W2993964230 hasConcept C111113717 @default.
• W2993964230 hasConcept C112705442 @default.
• W2993964230 hasConcept C126322002 @default.
• W2993964230 hasConcept C143998085 @default.
• W2993964230 hasConcept C168563851 @default.
• W2993964230 hasConcept C18031839 @default.
• W2993964230 hasConcept C203092338 @default.
• W2993964230 hasConcept C2777058707 @default.
• W2993964230 hasConcept C2778476033 @default.
• W2993964230 hasConcept C2779338263 @default.
• W2993964230 hasConcept C2780653079 @default.
• W2993964230 hasConcept C44249647 @default.
• W2993964230 hasConcept C59491497 @default.
• W2993964230 hasConcept C71924100 @default.
• W2993964230 hasConcept C90924648 @default.
• W2993964230 hasConceptScore W2993964230C111113717 @default.
• W2993964230 hasConceptScore W2993964230C112705442 @default.
• W2993964230 hasConceptScore W2993964230C126322002 @default.
• W2993964230 hasConceptScore W2993964230C143998085 @default.
• W2993964230 hasConceptScore W2993964230C168563851 @default.
• W2993964230 hasConceptScore W2993964230C18031839 @default.
• W2993964230 hasConceptScore W2993964230C203092338 @default.
• W2993964230 hasConceptScore W2993964230C2777058707 @default.
• W2993964230 hasConceptScore W2993964230C2778476033 @default.
• W2993964230 hasConceptScore W2993964230C2779338263 @default.
• W2993964230 hasConceptScore W2993964230C2780653079 @default.
• W2993964230 hasConceptScore W2993964230C44249647 @default.
• W2993964230 hasConceptScore W2993964230C59491497 @default.
• W2993964230 hasConceptScore W2993964230C71924100 @default.
• W2993964230 hasConceptScore W2993964230C90924648 @default.
• W2993964230 hasFunder F4320307765 @default.
• W2993964230 hasIssue "2" @default.
• W2993964230 hasLocation W29939642301 @default.
• W2993964230 hasLocation W29939642302 @default.
• W2993964230 hasLocation W29939642303 @default.
• W2993964230 hasLocation W29939642304 @default.
• W2993964230 hasLocation W29939642305 @default.
• W2993964230 hasOpenAccess W2993964230 @default.
• W2993964230 hasPrimaryLocation W29939642301 @default.
• W2993964230 hasRelatedWork W1594335059 @default.
• W2993964230 hasRelatedWork W2062186653 @default.
• W2993964230 hasRelatedWork W2073341443 @default.
• W2993964230 hasRelatedWork W2092717964 @default.
• W2993964230 hasRelatedWork W2165831472 @default.
• W2993964230 hasRelatedWork W2412172283 @default.
• W2993964230 hasRelatedWork W2587997350 @default.
• W2993964230 hasRelatedWork W3029070336 @default.
• W2993964230 hasRelatedWork W3112466335 @default.

• next